Ropes & Gray Represents Johnson & Johnson in its $1B Aragon Buyout
A team of Ropes & Gray attorneys is advising Johnson & Johnson in its acquisition of Aragon Pharmaceuticals, Inc., including rights to its second generation prostate cancer drug ARN-509, for $650 million in cash upfront and up to $350 million in contingent payments. The deal enhances Johnson & Johnson’s leadership in prostate cancer drug development, which is one of its main areas of focus, and provides the potential for novel approaches to treat prostate cancer patients.
The Ropes & Gray team included private equity transactions associates Michael Gilbert and Charlie Boer.
Articles in The Deal Pipeline and Law360 reported on this deal.